Fig. 2

GSK690 specifically inhibits GC cells harboring TP53 Frameshift ^NLS. A Immunoblotting of baseline expression levels of p53 in GC cells with different mutation types was performed. B Schematic diagram of screening epigenetic drugs for the specific treatment of TP53 GC was created. C Sequential treatment of GC cells with TP53 wild-type, TP53 hotspot mutations, and TP53 Frameshift ^NLS was conducted using individual histone demethylase inhibitor compounds (5 μM) from a library, followed by CCK-8 assay to estimate inhibition rates and generate a heatmap. D Predicted binding mode of GSK690 in the LSD1 active site (9FWG). Visualized using AutoDock Vina and Pymol. E, F GC cells were treated with GSK690 at different concentrations, and the inhibition rates were calculated using the CCK-8 assay. The IC₅₀ values of GSK690 in various GC cell lines were derived from the fitted curves, and a heatmap was generated. The relevant IC₅₀ data for the heatmap could be found in Fig. S2A